Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)

• DOI: 10.1007/s00259-020-04797-9
• Publication Date: 2020-05-08T01:02:32Z
• Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Richard P. Baum; Robert Seifert; Katharina Kessel; Martin Bögemann; Harshad R Kulkarni; Jingjing Zhang; Carolin Gerke; Rolf Fimmers; Clemens Kratochwil; Hendrik Rathke; Harun Ilhan; Johanna Maffey-St...; Mike Sathekge; Levent Kabasakal; Francisco Osvaldo...; Kalevi Kairemo; Masha Maharaj; Diana Paez; Irene Virgolini
• Keywords: Enzalutamide; Cabazitaxel; Univariate analysis

Abstract Introduction The impact of prior therapies, especially chemotherapy, on overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) receiving [ 177 Lu]Lu-PSMA-617 therapy has been the subject controversy. Therefore, WARMTH decided to plan a multicenter retrospective analysis (the “617 trial”) evaluate response rate and OS as well therapies more than 300 treated Lu-PSMA-617. Materials methods data 631 metastatic CRPC (mCRPC) from 11 different clinics were evaluated. According inclusion exclusion criteria, all had have received at least abiraterone or enzalutamide therapy. divided into three groups: who avoided for whom chemotherapy was contraindicated. Results included 416 patients, median age 71.9 years. At time analysis, 87 (20,9%) still alive. A total 53.6% both enzalutamide; 75.5% 26.4% history docetaxel cabazitaxel, respectively. 20.4% Ra-223. 11.1 months. Prior existence bone liver metastases, Eastern Cooperative Oncology Group (ECOG) status, significant prognosticators worse univariate multivariate analyses. Patients without any showed significantly longer (14.6 months). one two lines followed by respectively, 10.9 months 8.9 There no difference between not other did OS. Conclusion In present chemotherapy-naïve mCRPC chemotherapy. This remained independent besides presence metastases negative survival, whereas an ECOG 0–1 is associated